Patient preferences in the management of hidradenitis suppurativa: results of a multinational discrete choice experiment in Europe

Willems, Damon, Hinzpeter, Eva-Lotta, Van der Zee, Hessel H., Sayed, Christopher J., Ingram, John R. ORCID: https://orcid.org/0000-0002-5257-1142, Beaudart, Charlotte, Evers, Silvia M. A. A. and Hiligsmann, Mickael 2023. Patient preferences in the management of hidradenitis suppurativa: results of a multinational discrete choice experiment in Europe. The Patient - Patient-Centered Outcomes Research 16 (2) , pp. 153-164. 10.1007/s40271-022-00614-7

Preview

PDF - Published Version Available under License Creative Commons Attribution Non-commercial. Download (1MB) | Preview

Abstract

Background and Objective Hidradenitis suppurativa is a chronic inflammatory skin disease that can lead to a substantial reduction in quality of life. Recent studies revealed high levels of unmet care needs of patients with hidradenitis suppurativa, but their preferences in treatment decision making have scarcely been investigated. This study aimed to reveal which treatment attributes adult patients with HS in Europe consider most important in treatment decision-making. Methods A discrete choice experiment was conducted with adult patients with hidradenitis suppurativa in Europe to reveal which treatment attributes are most important when making treatment decisions. Participants were presented with 15 sets of two treatment options and asked for each to choose the treatment they preferred. The treatments were characterized by six attributes informed by a prior literature review and qualitative research: effectiveness, pain reduction, duration of treatment benefit, risk of mild adverse event, risk of serious infection, and mode of administration. A random parameter logit model was used to estimate patients’ preferences with additional subgroup and latent class models used to explore any differences in preferences across patient groups. Results Two hundred and nineteen adult patients with hidradenitis suppurativa were included in the analysis (90% women, mean age 38 years). For all six treatment attributes, significant differences were observed between levels. Given the range of levels of each attribute, the most important treatment attributes were effectiveness (47.9%), followed by pain reduction (17.3%), annual risk of a mild adverse event (14.4%), annual risk of a serious infection (10.3%), mode of administration (5.3%), and duration of treatment benefit (4.8%). Higher levels of effectiveness, namely a 75% or 100% reduction in the abscess and inflammatory nodule count, were preferred over levels of effectiveness primarily investigated in randomized clinical trials of hidradenitis suppurativa (a 50% reduction). Results were largely consistent across subgroups and three latent class groups were identified. Conclusions This study revealed the most important treatment characteristics for patients with hidradenitis suppurativa that can help inform joint patient-physician decision making in the management of hidradenitis suppurativa. Designing future hidradenitis suppurativa treatments according to stated preferences, namely, to offer higher levels of effectiveness and pain improvement without higher risks of adverse events, may increase patients’ treatment concordance and lead to improved disease management outcomes.

Item Type:	Article
Date Type:	Published Online
Status:	Published
Schools:	Medicine
Publisher:	Springer
ISSN:	1178-1653
Date of First Compliant Deposit:	10 February 2023
Date of Acceptance:	15 December 2022
Last Modified:	03 May 2023 20:23
URI:	https://orca.cardiff.ac.uk/id/eprint/156886

Actions (repository staff only)

Edit Item